Autopsy report · NCT03343600

Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

“The trial is terminated due to the extremely low recruitment rate.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 10 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Taiwan University Hospital

Sponsor type

University, hospital or other

Conditions

Patients Who Have Received Allo-HSCT

Interventions

Imatinib; Placebo

Participants

5

Sites

5

Countries

Taiwan

Trials that died the same way

• Effects of Upper Extremity Rehabilitation Using Smart Glove in Stroke Patients
  “The trial was prematurely terminated due to slow recruitment.” (86% match in meaning)
• Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
  “Due to the low recruitment rate since the start of the trial” (83% match in meaning)
• Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme.
  “The decision to terminate the trial was based on the slow rate of recruitment across the programme of studies” (81% match in meaning)
• Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
  “The trial was prematurely terminated. Termination was not because of safety concerns but due to slow recruitment.” (81% match in meaning)
• Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
  “The trial was terminated early on 05 October 2022 due to non-feasibility and poor recruitment and not based on safety concerns.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.